FDA approved a subcutaneous starting dose of lecanemab‑irmb (Leqembi Iqlik) for early Alzheimer’s disease. It provides an at‑home injection option that could increase patient adoption and expand the drug’s market reach. Who is involved: Eisai (partner of BioArctic), the US FDA, and patients with early Alzheimer’s.. Likely next: Eisai intends to launch the subcutaneous formulation in late August 2026 and will pursue reimbursement negotiations with payers.. On July 13, 2026, Eisai announced that the US FDA approved a supplemental Biologics License Application for a once‑weekly lecanemab‑irmb subcutaneous injection to be used as a starting dose for early Alzheimer’s disease. The approval follows earlier clearance of the intravenous formulation and enables patients to initiate therapy at home, similar to insulin or GLP‑1 regimens. Eisai plans to launch the subcutaneous product in late August 2026, with pricing and reimbursement details yet to be disclosed. The move positions Leqembi Iqlik alongside other subcutaneous biologics that have shown improved adherence and market penetration. Likely next events: Eisai plans U.S. launch of LEQEMBI IQLIK subcutaneous initiation dose in late August 2026. BioArctic expects royalty payments tied to subcutaneous sales to begin Q3 2026. FDA may review additional sBLAs for maintenance dosing of subcutaneous lecanemab later in 2026. Sectors affected: Alzheimer’s disease therapeutics biotechnology subcutaneous drug delivery Regulatory implications: Reimbursement agencies may need to create new HCPCS codes for weekly subcutaneous dosing. Historical parallels: FDA approval of intravenous aducanumab (Aduhelm) for Alzheimer’s in June 2021. FDA approval of subcutaneous donanemab (Kisunla) for Alzheimer’s in March 2024. FDA approval of subcutaneous semaglutide (Wegovy) for obesity in June 2021, demonstrating success of at‑home injection models.
INTELLIGENCE
Social Pulse
AI estimate · not scraped